Search Results: Breast Cancer (44 results)
ShareForCures: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry
https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.
Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)
https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study
Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.
Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.
A clinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer: VERITAC-2
https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies
Treatment
A clinical trial for ER-positive, HER2-negative advanced breast cancer
Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.
* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).
Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)
https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u
Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer
Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.
Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/285/
Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.
Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:
- For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.
- People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor
Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.
Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:
- People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.
- For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.
Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)
https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors
Quality of Life
Women diagnosed with breast cancer between the ages of 15-39
The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
The WISDOM Study: Women Informed to Screen Depending on Measures of Risk
https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study
Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
Study for Women at Increased Risk of Developing Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/257/study-for-women-at-increased-risk-of-developing-breast-cancer
Prevention
This study will create a system to assess an individual’s risk of breast cancer
This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.
Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation.
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.
Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation
Prevention
People with a BRCA1 or BRCA2 mutation
This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Self -Perception and Intimacy After the Cancer Experience (SPICE)
https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
Survey for cancer survivors ages 18-39 years old about sexual self-concept, sexual health knowledge, relationships and body image.
Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening
https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening
Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.
Researchers at the Mayo Clinic and McGill University are partnering with FORCE on a survey of women who have inherited mutations in BRCA1, BRCA2 or other genes (including PALB2, ATM, CHEK2, and others) related to increased breast cancer risk. We are interested in the effects of testing positive for an inherited mutation on decisions about the timing of pregnancy, breastfeeding, breast cancer screening and risk-reducing surgery.
Opening the Conversation
https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation
Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners
This is a clinical trial sponsored by the American Cancer Society, where we will be testing the helpfulness of two programs designed to teach breast and gynecological cancer survivors and their partners to communicate and cope with physical, emotional, and relationship challenges after cancer. The programs are conducted entirely via videoconference (Zoom), so neither you nor your partner would have to travel anywhere to participate.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer
Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer
The purpose of this study is to test whether acupuncture can improve thinking and memory difficulties in breast cancer survivors. Researchers will look at whether acupuncture improves memory, thinking and sleep in breast cancer survivors. This study will also look at the link between lack of sleep and thinking difficulties.
Restoring Sensation after DIEP Flap Reconstruction
https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction
Prevention
Study for people undergoing DIEP flap reconstruction
The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap).
Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/225/effects-of-occupational-therapy-telehealth-intervention-on-cancer-related-cognitive-impairment-in-breast-cancer-survivors
Quality of Life
Telehealth study for breast cancer survivors with memory issues
The purpose of this study is to look at the effects and ease of use of occupational therapy delivered by telehealth on activity performance, memory and quality of life in breast cancer survivors. Participants will complete all sessions from home via Zoom videoconferencing. This is a 2-arm randomized control trial, which means that each participant will be randomly assigned to one of two groups. Participants will complete the same number of sessions regardless of which group they are assigned to.
Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors
Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer
Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.
Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer
https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer
Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer
This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.
We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care
https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Prevention
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.
Cancer Experience Registry
https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer
Prevention
The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).
The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Treatment
Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit the E-Reach registration page.
RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident
Prevention
The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.
Genomic Services Research Program Study for People with Unexpected Genetic Results
https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results
Prevention
A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.
This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)
https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job
Quality of Life
The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.
Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)
https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project
Quality of Life
ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time.
ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.
The web-based survey can be accessed through this hypterlink.
Then entering code: PYCYHXD3A
RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer
https://www.facingourrisk.org/research-clinical-trials/study/192/restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer
People with stage 1-3 cancer
Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.
PHACT Study: Population Health and Cancer Testing
https://www.facingourrisk.org/research-clinical-trials/study/75/phact-study
NOTE: The PHACT study is no longer recruiting patients.
Making Genetic Testing Accessible (MAGENTA)
https://www.facingourrisk.org/research-clinical-trials/study/27/making-genetic-testing-accessible-magenta
The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer. NOTE: This study has closed for enrollment.
Additional Results on Clinicaltrials.gov Breast Cancer
795 results
[18F] F-GLN by PET/CT in Breast Cancer
NCT ID: NCT03863457 (https://classic.clinicaltrials.gov/show/NCT03863457)
First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT ID: NCT05304962 (https://classic.clinicaltrials.gov/show/NCT05304962)
SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://classic.clinicaltrials.gov/show/NCT04360330)
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://classic.clinicaltrials.gov/show/NCT02926729)
Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening
NCT ID: NCT03861975 (https://classic.clinicaltrials.gov/show/NCT03861975)
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
NCT ID: NCT05504707 (https://classic.clinicaltrials.gov/show/NCT05504707)
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT ID: NCT03765983 (https://classic.clinicaltrials.gov/show/NCT03765983)
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://classic.clinicaltrials.gov/show/NCT05074290)
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
NCT ID: NCT04651452 (https://classic.clinicaltrials.gov/show/NCT04651452)
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
NCT ID: NCT05051631 (https://classic.clinicaltrials.gov/show/NCT05051631)
EXERT-BCN: An Exercise and Nutrition Regimen to Designed to Improve Body Composition After Treatment for Breast Cancer
NCT ID: NCT05978960 (https://classic.clinicaltrials.gov/show/NCT05978960)
Exercise Timing in Breast Cancer Patients
NCT ID: NCT05821244 (https://classic.clinicaltrials.gov/show/NCT05821244)
Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors
NCT ID: NCT05931874 (https://classic.clinicaltrials.gov/show/NCT05931874)
FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer
NCT ID: NCT03212170 (https://classic.clinicaltrials.gov/show/NCT03212170)
Impact of Home-based Aerobic and Strength Exercises During Chemotherapy for Early Breast Cancer on Biomarkers of Aging
NCT ID: NCT03761706 (https://classic.clinicaltrials.gov/show/NCT03761706)
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://classic.clinicaltrials.gov/show/NCT05968157)
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
NCT ID: NCT06229392 (https://classic.clinicaltrials.gov/show/NCT06229392)
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://classic.clinicaltrials.gov/show/NCT05505643)
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT ID: NCT04270149 (https://classic.clinicaltrials.gov/show/NCT04270149)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://classic.clinicaltrials.gov/show/NCT05378464)
Strength After Breast Cancer
NCT ID: NCT06052488 (https://classic.clinicaltrials.gov/show/NCT06052488)
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT ID: NCT03742245 (https://classic.clinicaltrials.gov/show/NCT03742245)
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT ID: NCT05810025 (https://classic.clinicaltrials.gov/show/NCT05810025)
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://classic.clinicaltrials.gov/show/NCT05950945)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://classic.clinicaltrials.gov/show/NCT03694756)
Promoting Resilience in Women With Breast Cancer
NCT ID: NCT06133348 (https://classic.clinicaltrials.gov/show/NCT06133348)
HIIT Following Breast Cancer Chemotherapy
NCT ID: NCT05913713 (https://classic.clinicaltrials.gov/show/NCT05913713)
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://classic.clinicaltrials.gov/show/NCT04768426)
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://classic.clinicaltrials.gov/show/NCT04039230)
Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://classic.clinicaltrials.gov/show/NCT05464667)
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://classic.clinicaltrials.gov/show/NCT04965064)
3D Printed Breast Models in the Surgical Management of Breast Cancer
NCT ID: NCT05755984 (https://classic.clinicaltrials.gov/show/NCT05755984)
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT ID: NCT06081127 (https://classic.clinicaltrials.gov/show/NCT06081127)
Improving Communication and Adherence in Black Breast Cancer Survivors (Sisters Informing Sisters)
NCT ID: NCT05334732 (https://classic.clinicaltrials.gov/show/NCT05334732)
Adherence Intervention in Patients With Metastatic Breast Cancer
NCT ID: NCT06121453 (https://classic.clinicaltrials.gov/show/NCT06121453)
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://classic.clinicaltrials.gov/show/NCT05766891)
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
NCT ID: NCT05625659 (https://classic.clinicaltrials.gov/show/NCT05625659)
Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care
NCT ID: NCT05483283 (https://classic.clinicaltrials.gov/show/NCT05483283)
CAR T Cells in Mesothelin-Expressing Breast Cancer
NCT ID: NCT05623488 (https://classic.clinicaltrials.gov/show/NCT05623488)
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
NCT ID: NCT06361056 (https://classic.clinicaltrials.gov/show/NCT06361056)
FES BPET-DBT in Newly Diagnosed Breast Cancer
NCT ID: NCT05659797 (https://classic.clinicaltrials.gov/show/NCT05659797)
Exercise Post-Diagnosis of Breast Cancer
NCT ID: NCT04013568 (https://classic.clinicaltrials.gov/show/NCT04013568)
All-extremity Exercise During Breast Cancer Chemotherapy
NCT ID: NCT04914663 (https://classic.clinicaltrials.gov/show/NCT04914663)
Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer
NCT ID: NCT05609435 (https://classic.clinicaltrials.gov/show/NCT05609435)
Pilot Study of a MIND Diet Intervention in Women Undergoing Active Treatment for Breast Cancer
NCT ID: NCT05984888 (https://classic.clinicaltrials.gov/show/NCT05984888)
Evaluate Impact of Exercise Program on Fatigue in Breast Cancer During Chemotherapy
NCT ID: NCT05704842 (https://classic.clinicaltrials.gov/show/NCT05704842)
Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://classic.clinicaltrials.gov/show/NCT05665660)
Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT ID: NCT05130840 (https://classic.clinicaltrials.gov/show/NCT05130840)
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT ID: NCT03025035 (https://classic.clinicaltrials.gov/show/NCT03025035)
Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors
NCT ID: NCT05615753 (https://classic.clinicaltrials.gov/show/NCT05615753)
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://classic.clinicaltrials.gov/show/NCT06127979)
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT ID: NCT04756765 (https://classic.clinicaltrials.gov/show/NCT04756765)
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT ID: NCT05183126 (https://classic.clinicaltrials.gov/show/NCT05183126)
Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors
NCT ID: NCT05417451 (https://classic.clinicaltrials.gov/show/NCT05417451)
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT ID: NCT05675579 (https://classic.clinicaltrials.gov/show/NCT05675579)
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://classic.clinicaltrials.gov/show/NCT05856773)
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT ID: NCT03272334 (https://classic.clinicaltrials.gov/show/NCT03272334)
Couples' QOL in Metastatic Breast Cancer
NCT ID: NCT05636943 (https://classic.clinicaltrials.gov/show/NCT05636943)
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT ID: NCT05633979 (https://classic.clinicaltrials.gov/show/NCT05633979)
Promoting Informed Choice for Breast Cancer Screening: A Longitudinal Study
NCT ID: NCT05838417 (https://classic.clinicaltrials.gov/show/NCT05838417)
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://classic.clinicaltrials.gov/show/NCT06085742)
Assessing the Benefit of Art & Music Therapy on Quality of Life in Patients With Breast Cancer
NCT ID: NCT04493034 (https://classic.clinicaltrials.gov/show/NCT04493034)
A Comprehensive Oncology Rehabilitation and Exercise (CORE) Program Among Breast Cancer Survivors
NCT ID: NCT04594473 (https://classic.clinicaltrials.gov/show/NCT04594473)
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
NCT ID: NCT05957042 (https://classic.clinicaltrials.gov/show/NCT05957042)
Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer
NCT ID: NCT03400215 (https://classic.clinicaltrials.gov/show/NCT03400215)
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT ID: NCT03820141 (https://classic.clinicaltrials.gov/show/NCT03820141)
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
NCT ID: NCT05042687 (https://classic.clinicaltrials.gov/show/NCT05042687)
A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
NCT ID: NCT04040569 (https://classic.clinicaltrials.gov/show/NCT04040569)
Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://classic.clinicaltrials.gov/show/NCT05259410)
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
NCT ID: NCT05243641 (https://classic.clinicaltrials.gov/show/NCT05243641)
Effectiveness of AI Genetic Counseling Program vs In-person Genetic Counseling in Breast Cancer
NCT ID: NCT04354675 (https://classic.clinicaltrials.gov/show/NCT04354675)
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT ID: NCT05933395 (https://classic.clinicaltrials.gov/show/NCT05933395)
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
NCT ID: NCT03712813 (https://classic.clinicaltrials.gov/show/NCT03712813)
Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://classic.clinicaltrials.gov/show/NCT04796220)
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT ID: NCT02958774 (https://classic.clinicaltrials.gov/show/NCT02958774)
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://classic.clinicaltrials.gov/show/NCT05528133)
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
NCT ID: NCT06027268 (https://classic.clinicaltrials.gov/show/NCT06027268)
Magnetic Resonance Imaging of Breast Cancer
NCT ID: NCT01035112 (https://classic.clinicaltrials.gov/show/NCT01035112)
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://classic.clinicaltrials.gov/show/NCT04990921)
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT ID: NCT05716516 (https://classic.clinicaltrials.gov/show/NCT05716516)
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT ID: NCT04243616 (https://classic.clinicaltrials.gov/show/NCT04243616)
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://classic.clinicaltrials.gov/show/NCT05305924)
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT ID: NCT05959291 (https://classic.clinicaltrials.gov/show/NCT05959291)
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://classic.clinicaltrials.gov/show/NCT04523857)
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://classic.clinicaltrials.gov/show/NCT04891068)
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT ID: NCT02807597 (https://classic.clinicaltrials.gov/show/NCT02807597)
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://classic.clinicaltrials.gov/show/NCT04020575)
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://classic.clinicaltrials.gov/show/NCT05748834)
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
NCT ID: NCT04332588 (https://classic.clinicaltrials.gov/show/NCT04332588)
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
NCT ID: NCT02732171 (https://classic.clinicaltrials.gov/show/NCT02732171)
Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
NCT ID: NCT04968964 (https://classic.clinicaltrials.gov/show/NCT04968964)
Effect of Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer
NCT ID: NCT06019988 (https://classic.clinicaltrials.gov/show/NCT06019988)
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://classic.clinicaltrials.gov/show/NCT04427293)
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT ID: NCT05187832 (https://classic.clinicaltrials.gov/show/NCT05187832)
Functional Precision Oncology for Metastatic Breast Cancer
NCT ID: NCT04450706 (https://classic.clinicaltrials.gov/show/NCT04450706)
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT ID: NCT04273555 (https://classic.clinicaltrials.gov/show/NCT04273555)
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
NCT ID: NCT04364672 (https://classic.clinicaltrials.gov/show/NCT04364672)
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://classic.clinicaltrials.gov/show/NCT05130801)
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://classic.clinicaltrials.gov/show/NCT06239467)
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT ID: NCT04568616 (https://classic.clinicaltrials.gov/show/NCT04568616)
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
NCT ID: NCT04542135 (https://classic.clinicaltrials.gov/show/NCT04542135)
Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer
NCT ID: NCT05318469 (https://classic.clinicaltrials.gov/show/NCT05318469)
Study of Stereotactic Radiotherapy for Breast Cancer
NCT ID: NCT03043794 (https://classic.clinicaltrials.gov/show/NCT03043794)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://classic.clinicaltrials.gov/show/NCT06026657)
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT ID: NCT04573231 (https://classic.clinicaltrials.gov/show/NCT04573231)
mHealth for Breast Cancer Survivors With Insomnia
NCT ID: NCT05233800 (https://classic.clinicaltrials.gov/show/NCT05233800)
Breast Cancer Survivor Educational Intervention
NCT ID: NCT05700396 (https://classic.clinicaltrials.gov/show/NCT05700396)
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
NCT ID: NCT06100874 (https://classic.clinicaltrials.gov/show/NCT06100874)
Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer
NCT ID: NCT05101564 (https://classic.clinicaltrials.gov/show/NCT05101564)
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT ID: NCT04965688 (https://classic.clinicaltrials.gov/show/NCT04965688)
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
NCT ID: NCT06228768 (https://classic.clinicaltrials.gov/show/NCT06228768)
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03801369 (https://classic.clinicaltrials.gov/show/NCT03801369)
A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction
NCT ID: NCT05806138 (https://classic.clinicaltrials.gov/show/NCT05806138)
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
NCT ID: NCT03824145 (https://classic.clinicaltrials.gov/show/NCT03824145)
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
NCT ID: NCT05374915 (https://classic.clinicaltrials.gov/show/NCT05374915)
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT ID: NCT05676255 (https://classic.clinicaltrials.gov/show/NCT05676255)
Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT ID: NCT05472792 (https://classic.clinicaltrials.gov/show/NCT05472792)
Telemonitoring Hypertension and Breast Cancer
NCT ID: NCT05574686 (https://classic.clinicaltrials.gov/show/NCT05574686)
Cardiac Rehabilitation to Improve Breast Cancer Outcomes
NCT ID: NCT05867667 (https://classic.clinicaltrials.gov/show/NCT05867667)
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
NCT ID: NCT04458532 (https://classic.clinicaltrials.gov/show/NCT04458532)
MUSE-S Headband System for Improving Anxiety and Insomnia Among Breast Cancer Survivors
NCT ID: NCT06274034 (https://classic.clinicaltrials.gov/show/NCT06274034)
Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://classic.clinicaltrials.gov/show/NCT04074720)
Pioglitazone Therapy Targeting Fatigue in Breast Cancer
NCT ID: NCT05013255 (https://classic.clinicaltrials.gov/show/NCT05013255)
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT ID: NCT05553522 (https://classic.clinicaltrials.gov/show/NCT05553522)
ICG and SLN Mapping
NCT ID: NCT05859971 (https://classic.clinicaltrials.gov/show/NCT05859971)
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT ID: NCT05812924 (https://classic.clinicaltrials.gov/show/NCT05812924)
Acute Exercise Intervention in Breast Cancer Survivors
NCT ID: NCT03779867 (https://classic.clinicaltrials.gov/show/NCT03779867)
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer
NCT ID: NCT06219434 (https://classic.clinicaltrials.gov/show/NCT06219434)
Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Breast Cancer
NCT ID: NCT05787834 (https://classic.clinicaltrials.gov/show/NCT05787834)
Mobile-Health Delivery of Lifestyle Interventions for Women With Breast Cancer
NCT ID: NCT05132296 (https://classic.clinicaltrials.gov/show/NCT05132296)
Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
NCT ID: NCT04267796 (https://classic.clinicaltrials.gov/show/NCT04267796)
Promoting Genetic Counseling Among African American Women With a Family History of Breast Cancer
NCT ID: NCT04378751 (https://classic.clinicaltrials.gov/show/NCT04378751)
Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT ID: NCT04721886 (https://classic.clinicaltrials.gov/show/NCT04721886)
Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer
NCT ID: NCT04913064 (https://classic.clinicaltrials.gov/show/NCT04913064)
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast Cancer
NCT ID: NCT05325151 (https://classic.clinicaltrials.gov/show/NCT05325151)
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://classic.clinicaltrials.gov/show/NCT05325632)
Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
NCT ID: NCT05928325 (https://classic.clinicaltrials.gov/show/NCT05928325)
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT ID: NCT06115486 (https://classic.clinicaltrials.gov/show/NCT06115486)
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
NCT ID: NCT03945721 (https://classic.clinicaltrials.gov/show/NCT03945721)
Taking AIM at Breast Cancer
NCT ID: NCT04720209 (https://classic.clinicaltrials.gov/show/NCT04720209)
A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://classic.clinicaltrials.gov/show/NCT05408260)
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://classic.clinicaltrials.gov/show/NCT04824027)
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
NCT ID: NCT06072807 (https://classic.clinicaltrials.gov/show/NCT06072807)
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://classic.clinicaltrials.gov/show/NCT04674306)
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT ID: NCT03439735 (https://classic.clinicaltrials.gov/show/NCT03439735)
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://classic.clinicaltrials.gov/show/NCT06139107)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://classic.clinicaltrials.gov/show/NCT05288777)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://classic.clinicaltrials.gov/show/NCT06006806)
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT ID: NCT06260332 (https://classic.clinicaltrials.gov/show/NCT06260332)
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://classic.clinicaltrials.gov/show/NCT05524584)
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT ID: NCT05150652 (https://classic.clinicaltrials.gov/show/NCT05150652)
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT ID: NCT05826964 (https://classic.clinicaltrials.gov/show/NCT05826964)
A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
NCT ID: NCT03729115 (https://classic.clinicaltrials.gov/show/NCT03729115)
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://classic.clinicaltrials.gov/show/NCT05595499)
Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC)
NCT ID: NCT06006299 (https://classic.clinicaltrials.gov/show/NCT06006299)
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
NCT ID: NCT05660083 (https://classic.clinicaltrials.gov/show/NCT05660083)
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://classic.clinicaltrials.gov/show/NCT04174352)
Inspiratory Muscle Training in Obese Breast Cancer Survivors
NCT ID: NCT05193149 (https://classic.clinicaltrials.gov/show/NCT05193149)
REJOIN Trial for Older Breast Cancer Survivors
NCT ID: NCT03955627 (https://classic.clinicaltrials.gov/show/NCT03955627)
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT ID: NCT06028022 (https://classic.clinicaltrials.gov/show/NCT06028022)
Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://classic.clinicaltrials.gov/show/NCT06086704)
A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation
NCT ID: NCT06258993 (https://classic.clinicaltrials.gov/show/NCT06258993)
Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients
NCT ID: NCT03847311 (https://classic.clinicaltrials.gov/show/NCT03847311)
Cardiometabolic Screening Program
NCT ID: NCT05386719 (https://classic.clinicaltrials.gov/show/NCT05386719)
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05756166 (https://classic.clinicaltrials.gov/show/NCT05756166)
Heart Health After Cancer Treatment (HEART-ACT)
NCT ID: NCT06055803 (https://classic.clinicaltrials.gov/show/NCT06055803)
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://classic.clinicaltrials.gov/show/NCT04454528)
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://classic.clinicaltrials.gov/show/NCT06042569)
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://classic.clinicaltrials.gov/show/NCT05376878)
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
NCT ID: NCT04493333 (https://classic.clinicaltrials.gov/show/NCT04493333)
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://classic.clinicaltrials.gov/show/NCT05069038)
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
NCT ID: NCT05703178 (https://classic.clinicaltrials.gov/show/NCT05703178)
Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
NCT ID: NCT04365569 (https://classic.clinicaltrials.gov/show/NCT04365569)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://classic.clinicaltrials.gov/show/NCT04923542)
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://classic.clinicaltrials.gov/show/NCT04265872)
Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy
NCT ID: NCT04724499 (https://classic.clinicaltrials.gov/show/NCT04724499)
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://classic.clinicaltrials.gov/show/NCT04998682)
Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://classic.clinicaltrials.gov/show/NCT04636710)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://classic.clinicaltrials.gov/show/NCT04315233)
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://classic.clinicaltrials.gov/show/NCT06245889)
Apollo Device for Metastatic Breast Cancer (MBC)
NCT ID: NCT04983342 (https://classic.clinicaltrials.gov/show/NCT04983342)
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT ID: NCT06145399 (https://classic.clinicaltrials.gov/show/NCT06145399)
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05447910 (https://classic.clinicaltrials.gov/show/NCT05447910)
YES Study - Newly Diagnosed/Metastatic Intervention
NCT ID: NCT04379414 (https://classic.clinicaltrials.gov/show/NCT04379414)
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://classic.clinicaltrials.gov/show/NCT05710328)
Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions
NCT ID: NCT02802553 (https://classic.clinicaltrials.gov/show/NCT02802553)
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://classic.clinicaltrials.gov/show/NCT02476786)
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
NCT ID: NCT03285412 (https://classic.clinicaltrials.gov/show/NCT03285412)
Breaking Through the Brain Fog: An Online Research Study
NCT ID: NCT05444231 (https://classic.clinicaltrials.gov/show/NCT05444231)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)
Metacognitive Strategy Training in Cancer-related Cognitive Impairment
NCT ID: NCT05505045 (https://classic.clinicaltrials.gov/show/NCT05505045)
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer
NCT ID: NCT06008158 (https://classic.clinicaltrials.gov/show/NCT06008158)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://classic.clinicaltrials.gov/show/NCT05464082)
The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
NCT ID: NCT05786014 (https://classic.clinicaltrials.gov/show/NCT05786014)
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://classic.clinicaltrials.gov/show/NCT04614194)
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://classic.clinicaltrials.gov/show/NCT05219695)
An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer
NCT ID: NCT06136923 (https://classic.clinicaltrials.gov/show/NCT06136923)
Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
NCT ID: NCT04973930 (https://classic.clinicaltrials.gov/show/NCT04973930)
Gut Microbe Composition, Exercise, and Breast Breast Cancer Survivors
NCT ID: NCT04088708 (https://classic.clinicaltrials.gov/show/NCT04088708)
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://classic.clinicaltrials.gov/show/NCT04521764)
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial
NCT ID: NCT04727632 (https://classic.clinicaltrials.gov/show/NCT04727632)
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer
NCT ID: NCT05996107 (https://classic.clinicaltrials.gov/show/NCT05996107)
SMART-ER: Symptom Monitoring With Patient-reported Outcomes
NCT ID: NCT05560685 (https://classic.clinicaltrials.gov/show/NCT05560685)
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
NCT ID: NCT03769415 (https://classic.clinicaltrials.gov/show/NCT03769415)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://classic.clinicaltrials.gov/show/NCT04563507)
ARTIDIS Nanomechanical Generated Measurements for Early Breast Lesions
NCT ID: NCT06085833 (https://classic.clinicaltrials.gov/show/NCT06085833)
Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer
NCT ID: NCT05746325 (https://classic.clinicaltrials.gov/show/NCT05746325)
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
NCT ID: NCT06057636 (https://classic.clinicaltrials.gov/show/NCT06057636)
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
NCT ID: NCT01984138 (https://classic.clinicaltrials.gov/show/NCT01984138)
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834 (https://classic.clinicaltrials.gov/show/NCT02290834)
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery
NCT ID: NCT04233385 (https://classic.clinicaltrials.gov/show/NCT04233385)
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://classic.clinicaltrials.gov/show/NCT04648904)
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT ID: NCT03995082 (https://classic.clinicaltrials.gov/show/NCT03995082)
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://classic.clinicaltrials.gov/show/NCT05846789)
3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer
NCT ID: NCT05704283 (https://classic.clinicaltrials.gov/show/NCT05704283)
Scalp Cooling in MBC
NCT ID: NCT04986579 (https://classic.clinicaltrials.gov/show/NCT04986579)
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT ID: NCT05340673 (https://classic.clinicaltrials.gov/show/NCT05340673)
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://classic.clinicaltrials.gov/show/NCT06185205)
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT ID: NCT04120246 (https://classic.clinicaltrials.gov/show/NCT04120246)
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT ID: NCT04871139 (https://classic.clinicaltrials.gov/show/NCT04871139)
A QoL Intervention for Young African American Breast Cancer Survivors
NCT ID: NCT05452681 (https://classic.clinicaltrials.gov/show/NCT05452681)
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT ID: NCT05456373 (https://classic.clinicaltrials.gov/show/NCT05456373)
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
NCT ID: NCT05394259 (https://classic.clinicaltrials.gov/show/NCT05394259)
Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction
NCT ID: NCT06153836 (https://classic.clinicaltrials.gov/show/NCT06153836)
Efficacy of Point Of Service Testing in MBC
NCT ID: NCT03983577 (https://classic.clinicaltrials.gov/show/NCT03983577)
An Escape Room Intervention to Help Improve Breast Cancer Patients' Ability to Navigate Online Access to Nutrition Information
NCT ID: NCT06193070 (https://classic.clinicaltrials.gov/show/NCT06193070)
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr
NCT ID: NCT05591547 (https://classic.clinicaltrials.gov/show/NCT05591547)
Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://classic.clinicaltrials.gov/show/NCT04049214)
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://classic.clinicaltrials.gov/show/NCT02977468)
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT ID: NCT04030507 (https://classic.clinicaltrials.gov/show/NCT04030507)
The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors
NCT ID: NCT05983380 (https://classic.clinicaltrials.gov/show/NCT05983380)
Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors
NCT ID: NCT05674578 (https://classic.clinicaltrials.gov/show/NCT05674578)
A Quality of Life Intervention (Y-AMBIENT) for Young African American With Stage I-III Breast Cancer
NCT ID: NCT05243056 (https://classic.clinicaltrials.gov/show/NCT05243056)
3D Ultrasound Breast Imaging
NCT ID: NCT04692818 (https://classic.clinicaltrials.gov/show/NCT04692818)
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
NCT ID: NCT04791384 (https://classic.clinicaltrials.gov/show/NCT04791384)
Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors
NCT ID: NCT04290897 (https://classic.clinicaltrials.gov/show/NCT04290897)
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
NCT ID: NCT04754412 (https://classic.clinicaltrials.gov/show/NCT04754412)
Identifying Decision Making Needs for Older Adult Women With Stage I-III Breast Cancer Considering Neoadjuvant or Adjuvant Chemotherapy
NCT ID: NCT05049746 (https://classic.clinicaltrials.gov/show/NCT05049746)
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT ID: NCT04717050 (https://classic.clinicaltrials.gov/show/NCT04717050)
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma
NCT ID: NCT04849871 (https://classic.clinicaltrials.gov/show/NCT04849871)
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT ID: NCT03941756 (https://classic.clinicaltrials.gov/show/NCT03941756)
Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women
NCT ID: NCT05298605 (https://classic.clinicaltrials.gov/show/NCT05298605)
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://classic.clinicaltrials.gov/show/NCT05095207)
Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®
NCT ID: NCT05825482 (https://classic.clinicaltrials.gov/show/NCT05825482)
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://classic.clinicaltrials.gov/show/NCT04348747)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://classic.clinicaltrials.gov/show/NCT05677802)
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT ID: NCT04445844 (https://classic.clinicaltrials.gov/show/NCT04445844)
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT ID: NCT06328738 (https://classic.clinicaltrials.gov/show/NCT06328738)
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
NCT ID: NCT06176261 (https://classic.clinicaltrials.gov/show/NCT06176261)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://classic.clinicaltrials.gov/show/NCT03796559)
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer
NCT ID: NCT04205903 (https://classic.clinicaltrials.gov/show/NCT04205903)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)
Monitoring Neoadjuvant Chemotherapy of Breast Cancer Using 3D Subharmonic Aided Pressure Estimation
NCT ID: NCT04715958 (https://classic.clinicaltrials.gov/show/NCT04715958)
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://classic.clinicaltrials.gov/show/NCT05319873)
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
NCT ID: NCT05975736 (https://classic.clinicaltrials.gov/show/NCT05975736)
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT ID: NCT05226663 (https://classic.clinicaltrials.gov/show/NCT05226663)
Biomarkers to Detect Endocrine Therapy Resistance
NCT ID: NCT06067503 (https://classic.clinicaltrials.gov/show/NCT06067503)
Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects
NCT ID: NCT03897270 (https://classic.clinicaltrials.gov/show/NCT03897270)
Prehabilitation to Revolutionize Oncology: Telehealth Exercise for Cognitive Triumphs (The PROTECT Trial)
NCT ID: NCT05716542 (https://classic.clinicaltrials.gov/show/NCT05716542)
Intraoperative Radiation Therapy (IORT) in DCIS
NCT ID: NCT03216421 (https://classic.clinicaltrials.gov/show/NCT03216421)
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://classic.clinicaltrials.gov/show/NCT05020860)
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer
NCT ID: NCT05417308 (https://classic.clinicaltrials.gov/show/NCT05417308)
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://classic.clinicaltrials.gov/show/NCT05245812)
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://classic.clinicaltrials.gov/show/NCT05491226)
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://classic.clinicaltrials.gov/show/NCT06129747)
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://classic.clinicaltrials.gov/show/NCT05256745)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://classic.clinicaltrials.gov/show/NCT04677816)
A Culturally Sensitive Social Support Intervention
NCT ID: NCT02946697 (https://classic.clinicaltrials.gov/show/NCT02946697)
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://classic.clinicaltrials.gov/show/NCT03449238)
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://classic.clinicaltrials.gov/show/NCT05608252)
Diabetes Care for Breast Cancer Patients
NCT ID: NCT05565534 (https://classic.clinicaltrials.gov/show/NCT05565534)
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://classic.clinicaltrials.gov/show/NCT03213041)
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT ID: NCT05535192 (https://classic.clinicaltrials.gov/show/NCT05535192)
SABR-CaRe in Early Stage Breast Cancer
NCT ID: NCT04959474 (https://classic.clinicaltrials.gov/show/NCT04959474)
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://classic.clinicaltrials.gov/show/NCT05693766)
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://classic.clinicaltrials.gov/show/NCT05557877)
ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://classic.clinicaltrials.gov/show/NCT05501704)
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://classic.clinicaltrials.gov/show/NCT05269160)
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT ID: NCT03796273 (https://classic.clinicaltrials.gov/show/NCT03796273)
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
NCT ID: NCT04305834 (https://classic.clinicaltrials.gov/show/NCT04305834)
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT ID: NCT04837209 (https://classic.clinicaltrials.gov/show/NCT04837209)
Exercise in Metastatic Breast Cancer: EMBody
NCT ID: NCT05468034 (https://classic.clinicaltrials.gov/show/NCT05468034)
Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT ID: NCT05684367 (https://classic.clinicaltrials.gov/show/NCT05684367)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://classic.clinicaltrials.gov/show/NCT05098210)
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://classic.clinicaltrials.gov/show/NCT06220214)
Together After Cancer
NCT ID: NCT05645471 (https://classic.clinicaltrials.gov/show/NCT05645471)
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT ID: NCT02095184 (https://classic.clinicaltrials.gov/show/NCT02095184)
A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer
NCT ID: NCT06188559 (https://classic.clinicaltrials.gov/show/NCT06188559)
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT ID: NCT05142358 (https://classic.clinicaltrials.gov/show/NCT05142358)
Cone Beam Breast CT for Breast Cancer Screening
NCT ID: NCT05036096 (https://classic.clinicaltrials.gov/show/NCT05036096)
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer
NCT ID: NCT03546686 (https://classic.clinicaltrials.gov/show/NCT03546686)
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients
NCT ID: NCT04443413 (https://classic.clinicaltrials.gov/show/NCT04443413)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://classic.clinicaltrials.gov/show/NCT02422641)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://classic.clinicaltrials.gov/show/NCT04234386)
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://classic.clinicaltrials.gov/show/NCT05230810)
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://classic.clinicaltrials.gov/show/NCT05455658)
Web-Based Symptom Monitoring and Self-Management Portal (YES) for Adolescent and Young Adult Breast Cancer Survivors
NCT ID: NCT04906200 (https://classic.clinicaltrials.gov/show/NCT04906200)
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT ID: NCT05954143 (https://classic.clinicaltrials.gov/show/NCT05954143)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://classic.clinicaltrials.gov/show/NCT03671044)
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://classic.clinicaltrials.gov/show/NCT04862585)
CanRestoreFunction Cancer-related Fatigue ( CRF )
NCT ID: NCT05868187 (https://classic.clinicaltrials.gov/show/NCT05868187)
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://classic.clinicaltrials.gov/show/NCT04993313)
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT ID: NCT06058650 (https://classic.clinicaltrials.gov/show/NCT06058650)
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT ID: NCT02760030 (https://classic.clinicaltrials.gov/show/NCT02760030)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://classic.clinicaltrials.gov/show/NCT04329065)
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://classic.clinicaltrials.gov/show/NCT05464810)
Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://classic.clinicaltrials.gov/show/NCT03789097)
Tonation Breathing Technique Method to Ease Aromatase Inhibitor-induced Joint and/or Muscle Pain
NCT ID: NCT05412953 (https://classic.clinicaltrials.gov/show/NCT05412953)
Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer
NCT ID: NCT05368428 (https://classic.clinicaltrials.gov/show/NCT05368428)
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT ID: NCT05251714 (https://classic.clinicaltrials.gov/show/NCT05251714)
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT ID: NCT04009044 (https://classic.clinicaltrials.gov/show/NCT04009044)
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
NCT ID: NCT06169371 (https://classic.clinicaltrials.gov/show/NCT06169371)
Mammogram Mail- and Phone-based Interventions
NCT ID: NCT05853848 (https://classic.clinicaltrials.gov/show/NCT05853848)
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT ID: NCT04946864 (https://classic.clinicaltrials.gov/show/NCT04946864)
Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT ID: NCT05807074 (https://classic.clinicaltrials.gov/show/NCT05807074)
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://classic.clinicaltrials.gov/show/NCT05774678)
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT ID: NCT05754749 (https://classic.clinicaltrials.gov/show/NCT05754749)
Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT ID: NCT05744557 (https://classic.clinicaltrials.gov/show/NCT05744557)
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT ID: NCT05731791 (https://classic.clinicaltrials.gov/show/NCT05731791)
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
NCT ID: NCT02926690 (https://classic.clinicaltrials.gov/show/NCT02926690)
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
NCT ID: NCT05496829 (https://classic.clinicaltrials.gov/show/NCT05496829)
Nipple Aspirate Fluid in Detecting Breast Cancer
NCT ID: NCT03715959 (https://classic.clinicaltrials.gov/show/NCT03715959)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://classic.clinicaltrials.gov/show/NCT05291507)
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
NCT ID: NCT05206331 (https://classic.clinicaltrials.gov/show/NCT05206331)
Evaluating the Use of Patient Navigation to Promote Timely Diagnostic Evaluation During the COVID-19 Pandemic
NCT ID: NCT05181722 (https://classic.clinicaltrials.gov/show/NCT05181722)
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
NCT ID: NCT04534010 (https://classic.clinicaltrials.gov/show/NCT04534010)
Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses
NCT ID: NCT06171607 (https://classic.clinicaltrials.gov/show/NCT06171607)
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
NCT ID: NCT04348123 (https://classic.clinicaltrials.gov/show/NCT04348123)
Improving Genetic Counseling for BRCA+ Mothers
NCT ID: NCT04258280 (https://classic.clinicaltrials.gov/show/NCT04258280)
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
NCT ID: NCT04225572 (https://classic.clinicaltrials.gov/show/NCT04225572)
mHealth Behavioral Cancer Pain Intervention for Medically Undeserved Patients
NCT ID: NCT04175639 (https://classic.clinicaltrials.gov/show/NCT04175639)
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT ID: NCT03321045 (https://classic.clinicaltrials.gov/show/NCT03321045)
Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy
NCT ID: NCT03238976 (https://classic.clinicaltrials.gov/show/NCT03238976)
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://classic.clinicaltrials.gov/show/NCT05637216)
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)
NCT ID: NCT05809752 (https://classic.clinicaltrials.gov/show/NCT05809752)
Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors
NCT ID: NCT03953157 (https://classic.clinicaltrials.gov/show/NCT03953157)
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT ID: NCT06018337 (https://classic.clinicaltrials.gov/show/NCT06018337)
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
NCT ID: NCT05056844 (https://classic.clinicaltrials.gov/show/NCT05056844)
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT ID: NCT04762979 (https://classic.clinicaltrials.gov/show/NCT04762979)
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://classic.clinicaltrials.gov/show/NCT04333706)
Project 1: Self-Triage by 2D Full-field Digital Mammography or Synthetic Images
NCT ID: NCT05960188 (https://classic.clinicaltrials.gov/show/NCT05960188)
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://classic.clinicaltrials.gov/show/NCT06275126)
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT ID: NCT04815083 (https://classic.clinicaltrials.gov/show/NCT04815083)
A Study of the Use of Acellular Dermal Matrix for Breast Reconstruction
NCT ID: NCT05316324 (https://classic.clinicaltrials.gov/show/NCT05316324)
Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT ID: NCT05223322 (https://classic.clinicaltrials.gov/show/NCT05223322)
Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community
NCT ID: NCT05314179 (https://classic.clinicaltrials.gov/show/NCT05314179)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://classic.clinicaltrials.gov/show/NCT05190978)
Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
NCT ID: NCT06082882 (https://classic.clinicaltrials.gov/show/NCT06082882)
Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://classic.clinicaltrials.gov/show/NCT05020574)
The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer Patients
NCT ID: NCT05226078 (https://classic.clinicaltrials.gov/show/NCT05226078)
Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors
NCT ID: NCT04965246 (https://classic.clinicaltrials.gov/show/NCT04965246)
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://classic.clinicaltrials.gov/show/NCT03909282)
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://classic.clinicaltrials.gov/show/NCT04904757)
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://classic.clinicaltrials.gov/show/NCT06295744)
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT ID: NCT03979508 (https://classic.clinicaltrials.gov/show/NCT03979508)
Empowering Latinas to Obtain Guideline Concordant Screenings
NCT ID: NCT05841355 (https://classic.clinicaltrials.gov/show/NCT05841355)
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT ID: NCT05289466 (https://classic.clinicaltrials.gov/show/NCT05289466)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://classic.clinicaltrials.gov/show/NCT05795101)
A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)
NCT ID: NCT05935891 (https://classic.clinicaltrials.gov/show/NCT05935891)
A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy
NCT ID: NCT05488145 (https://classic.clinicaltrials.gov/show/NCT05488145)
Well-Being After Breast Cancer Surgery
NCT ID: NCT04225585 (https://classic.clinicaltrials.gov/show/NCT04225585)
Intervening on Women's Health for Rural Young Breast Cancer Survivors
NCT ID: NCT05414812 (https://classic.clinicaltrials.gov/show/NCT05414812)
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT ID: NCT05780814 (https://classic.clinicaltrials.gov/show/NCT05780814)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://classic.clinicaltrials.gov/show/NCT03990896)
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma
NCT ID: NCT04252859 (https://classic.clinicaltrials.gov/show/NCT04252859)
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://classic.clinicaltrials.gov/show/NCT03934905)
Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants
NCT ID: NCT05978128 (https://classic.clinicaltrials.gov/show/NCT05978128)
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT ID: NCT05309655 (https://classic.clinicaltrials.gov/show/NCT05309655)
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
NCT ID: NCT02918474 (https://classic.clinicaltrials.gov/show/NCT02918474)
Psychosexual Educational Partners Program (PEPP)
NCT ID: NCT06253182 (https://classic.clinicaltrials.gov/show/NCT06253182)
Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
NCT ID: NCT02400060 (https://classic.clinicaltrials.gov/show/NCT02400060)
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT ID: NCT05190770 (https://classic.clinicaltrials.gov/show/NCT05190770)
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05654532 (https://classic.clinicaltrials.gov/show/NCT05654532)
Ultrahypofractionation and Normal Tissue Toxicity
NCT ID: NCT05912231 (https://classic.clinicaltrials.gov/show/NCT05912231)
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://classic.clinicaltrials.gov/show/NCT05351424)
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT ID: NCT06136884 (https://classic.clinicaltrials.gov/show/NCT06136884)
Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT ID: NCT05023967 (https://classic.clinicaltrials.gov/show/NCT05023967)
THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
NCT ID: NCT06388304 (https://classic.clinicaltrials.gov/show/NCT06388304)
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://classic.clinicaltrials.gov/show/NCT04886531)
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
NCT ID: NCT05921253 (https://classic.clinicaltrials.gov/show/NCT05921253)
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and Telegenetics
NCT ID: NCT05694559 (https://classic.clinicaltrials.gov/show/NCT05694559)
Patient Recall of Cancer Screening and Diagnosis
NCT ID: NCT05014295 (https://classic.clinicaltrials.gov/show/NCT05014295)
Opening the Conversation Study
NCT ID: NCT04806724 (https://classic.clinicaltrials.gov/show/NCT04806724)
3-D Super Resolution Ultrasound Microvascular Imaging
NCT ID: NCT04136912 (https://classic.clinicaltrials.gov/show/NCT04136912)
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://classic.clinicaltrials.gov/show/NCT04371913)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT ID: NCT04175210 (https://classic.clinicaltrials.gov/show/NCT04175210)
Onvansertib + Paclitaxel In TNBC
NCT ID: NCT05383196 (https://classic.clinicaltrials.gov/show/NCT05383196)
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients
NCT ID: NCT05585788 (https://classic.clinicaltrials.gov/show/NCT05585788)
Study Assessing QBS72S For Treating Brain Metastases
NCT ID: NCT05305365 (https://classic.clinicaltrials.gov/show/NCT05305365)
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
NCT ID: NCT04722341 (https://classic.clinicaltrials.gov/show/NCT04722341)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT ID: NCT05111561 (https://classic.clinicaltrials.gov/show/NCT05111561)
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
NCT ID: NCT05655598 (https://classic.clinicaltrials.gov/show/NCT05655598)
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT ID: NCT02484404 (https://classic.clinicaltrials.gov/show/NCT02484404)
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage
NCT ID: NCT05554211 (https://classic.clinicaltrials.gov/show/NCT05554211)
Losartan in Prevention of Radiation-Induced Heart Failure
NCT ID: NCT05607017 (https://classic.clinicaltrials.gov/show/NCT05607017)
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT ID: NCT04872166 (https://classic.clinicaltrials.gov/show/NCT04872166)
Leflunomide in Previously Treated Metastatic Triple Negative Cancers
NCT ID: NCT03709446 (https://classic.clinicaltrials.gov/show/NCT03709446)
Biennial CEM in Women With a Personal History of Breast Cancer
NCT ID: NCT06105749 (https://classic.clinicaltrials.gov/show/NCT06105749)
Testing Home-based Exercise Strategies in Underserved Minority Cancer Patients Undergoing Chemotherapy: the THRIVE Study
NCT ID: NCT05327452 (https://classic.clinicaltrials.gov/show/NCT05327452)
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://classic.clinicaltrials.gov/show/NCT01185132)
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
NCT ID: NCT05528263 (https://classic.clinicaltrials.gov/show/NCT05528263)
Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT ID: NCT04821141 (https://classic.clinicaltrials.gov/show/NCT04821141)
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://classic.clinicaltrials.gov/show/NCT05458674)
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT ID: NCT02927912 (https://classic.clinicaltrials.gov/show/NCT02927912)
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT ID: NCT05627960 (https://classic.clinicaltrials.gov/show/NCT05627960)
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://classic.clinicaltrials.gov/show/NCT04003038)
Peer Support For Young Adult Women With High Breast Cancer Risk
NCT ID: NCT04248257 (https://classic.clinicaltrials.gov/show/NCT04248257)
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT ID: NCT03696030 (https://classic.clinicaltrials.gov/show/NCT03696030)
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
NCT ID: NCT05029999 (https://classic.clinicaltrials.gov/show/NCT05029999)
Geriatric Assessment and Promotores (GAP) Pilot Feasibility Study
NCT ID: NCT06125145 (https://classic.clinicaltrials.gov/show/NCT06125145)
Improving Comprehensive Care of Cancer Patients
NCT ID: NCT05323409 (https://classic.clinicaltrials.gov/show/NCT05323409)
Sensory Restoration After DIEP Flap Neurotization
NCT ID: NCT04533373 (https://classic.clinicaltrials.gov/show/NCT04533373)
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
NCT ID: NCT06096623 (https://classic.clinicaltrials.gov/show/NCT06096623)
Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT ID: NCT05649072 (https://classic.clinicaltrials.gov/show/NCT05649072)
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)
Sacituzumab Govitecan In TNBC
NCT ID: NCT04230109 (https://classic.clinicaltrials.gov/show/NCT04230109)
Postoperative Opt-In Narcotics Treatment in Breast
NCT ID: NCT05078398 (https://classic.clinicaltrials.gov/show/NCT05078398)
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://classic.clinicaltrials.gov/show/NCT05563220)
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
NCT ID: NCT06257758 (https://classic.clinicaltrials.gov/show/NCT06257758)
Scalable Communication Modalities for Returning Genetic Research Results
NCT ID: NCT04407611 (https://classic.clinicaltrials.gov/show/NCT04407611)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://classic.clinicaltrials.gov/show/NCT04711824)
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT ID: NCT06206837 (https://classic.clinicaltrials.gov/show/NCT06206837)
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)
NCT ID: NCT05573555 (https://classic.clinicaltrials.gov/show/NCT05573555)
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT ID: NCT05596409 (https://classic.clinicaltrials.gov/show/NCT05596409)
Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
NCT ID: NCT06216574 (https://classic.clinicaltrials.gov/show/NCT06216574)
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://classic.clinicaltrials.gov/show/NCT04567420)
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
NCT ID: NCT05498155 (https://classic.clinicaltrials.gov/show/NCT05498155)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://classic.clinicaltrials.gov/show/NCT05412225)
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
NCT ID: NCT05909397 (https://classic.clinicaltrials.gov/show/NCT05909397)
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
NCT ID: NCT06150664 (https://classic.clinicaltrials.gov/show/NCT06150664)
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://classic.clinicaltrials.gov/show/NCT05774951)
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT ID: NCT04699630 (https://classic.clinicaltrials.gov/show/NCT04699630)
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
NCT ID: NCT05966584 (https://classic.clinicaltrials.gov/show/NCT05966584)
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT ID: NCT04841148 (https://classic.clinicaltrials.gov/show/NCT04841148)
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT ID: NCT05132582 (https://classic.clinicaltrials.gov/show/NCT05132582)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://classic.clinicaltrials.gov/show/NCT06103864)
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT ID: NCT06112379 (https://classic.clinicaltrials.gov/show/NCT06112379)
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT ID: NCT05548127 (https://classic.clinicaltrials.gov/show/NCT05548127)
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT ID: NCT05629585 (https://classic.clinicaltrials.gov/show/NCT05629585)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://classic.clinicaltrials.gov/show/NCT04862663)
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT04072952 (https://classic.clinicaltrials.gov/show/NCT04072952)
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT ID: NCT05374512 (https://classic.clinicaltrials.gov/show/NCT05374512)
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
NCT ID: NCT06125522 (https://classic.clinicaltrials.gov/show/NCT06125522)
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT ID: NCT05501886 (https://classic.clinicaltrials.gov/show/NCT05501886)
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT ID: NCT05654623 (https://classic.clinicaltrials.gov/show/NCT05654623)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://classic.clinicaltrials.gov/show/NCT03804944)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT ID: NCT05952557 (https://classic.clinicaltrials.gov/show/NCT05952557)
Ribociclib and Bicalutamide in AR+ TNBC
NCT ID: NCT03090165 (https://classic.clinicaltrials.gov/show/NCT03090165)
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
NCT ID: NCT05307705 (https://classic.clinicaltrials.gov/show/NCT05307705)
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT ID: NCT05143229 (https://classic.clinicaltrials.gov/show/NCT05143229)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://classic.clinicaltrials.gov/show/NCT03572374)
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT ID: NCT05163223 (https://classic.clinicaltrials.gov/show/NCT05163223)
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
NCT ID: NCT05570253 (https://classic.clinicaltrials.gov/show/NCT05570253)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://classic.clinicaltrials.gov/show/NCT06072612)
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05852691 (https://classic.clinicaltrials.gov/show/NCT05852691)
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT ID: NCT04906395 (https://classic.clinicaltrials.gov/show/NCT04906395)
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer
NCT ID: NCT05203445 (https://classic.clinicaltrials.gov/show/NCT05203445)
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
NCT ID: NCT04849364 (https://classic.clinicaltrials.gov/show/NCT04849364)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862 (https://classic.clinicaltrials.gov/show/NCT05646862)
Evexomostat Plus Alpelisib and Fulvestrant in Women With the PIK3CA Mutation With HR+/Her2- Breast Cancer
NCT ID: NCT05455619 (https://classic.clinicaltrials.gov/show/NCT05455619)
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT ID: NCT06110793 (https://classic.clinicaltrials.gov/show/NCT06110793)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://classic.clinicaltrials.gov/show/NCT03424005)
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer
NCT ID: NCT03255577 (https://classic.clinicaltrials.gov/show/NCT03255577)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://classic.clinicaltrials.gov/show/NCT03488693)
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://classic.clinicaltrials.gov/show/NCT04606030)
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT ID: NCT06099769 (https://classic.clinicaltrials.gov/show/NCT06099769)
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT ID: NCT03368729 (https://classic.clinicaltrials.gov/show/NCT03368729)
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT ID: NCT05207709 (https://classic.clinicaltrials.gov/show/NCT05207709)
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
NCT ID: NCT06001762 (https://classic.clinicaltrials.gov/show/NCT06001762)
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT ID: NCT06105632 (https://classic.clinicaltrials.gov/show/NCT06105632)
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT ID: NCT05696626 (https://classic.clinicaltrials.gov/show/NCT05696626)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://classic.clinicaltrials.gov/show/NCT05894239)
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT ID: NCT04961996 (https://classic.clinicaltrials.gov/show/NCT04961996)
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT ID: NCT04829604 (https://classic.clinicaltrials.gov/show/NCT04829604)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://classic.clinicaltrials.gov/show/NCT05879926)
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
NCT ID: NCT05963997 (https://classic.clinicaltrials.gov/show/NCT05963997)
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT ID: NCT04873362 (https://classic.clinicaltrials.gov/show/NCT04873362)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT ID: NCT05705401 (https://classic.clinicaltrials.gov/show/NCT05705401)
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT ID: NCT06075953 (https://classic.clinicaltrials.gov/show/NCT06075953)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
NCT ID: NCT05633654 (https://classic.clinicaltrials.gov/show/NCT05633654)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT ID: NCT05840211 (https://classic.clinicaltrials.gov/show/NCT05840211)
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT ID: NCT03412643 (https://classic.clinicaltrials.gov/show/NCT03412643)
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
NCT ID: NCT05949021 (https://classic.clinicaltrials.gov/show/NCT05949021)
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT ID: NCT04443348 (https://classic.clinicaltrials.gov/show/NCT04443348)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://classic.clinicaltrials.gov/show/NCT04588545)
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT ID: NCT03975647 (https://classic.clinicaltrials.gov/show/NCT03975647)
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT ID: NCT05963984 (https://classic.clinicaltrials.gov/show/NCT05963984)
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer
NCT ID: NCT03988595 (https://classic.clinicaltrials.gov/show/NCT03988595)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://classic.clinicaltrials.gov/show/NCT04852887)
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT ID: NCT05296798 (https://classic.clinicaltrials.gov/show/NCT05296798)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://classic.clinicaltrials.gov/show/NCT04802759)
ATEMPT 2.0: Adjuvant T-DM1 vs TH
NCT ID: NCT04893109 (https://classic.clinicaltrials.gov/show/NCT04893109)
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT ID: NCT06065748 (https://classic.clinicaltrials.gov/show/NCT06065748)
RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)
NCT ID: NCT05176756 (https://classic.clinicaltrials.gov/show/NCT05176756)
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
NCT ID: NCT02778685 (https://classic.clinicaltrials.gov/show/NCT02778685)
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
NCT ID: NCT04187898 (https://classic.clinicaltrials.gov/show/NCT04187898)
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT ID: NCT05306340 (https://classic.clinicaltrials.gov/show/NCT05306340)
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
NCT ID: NCT02993068 (https://classic.clinicaltrials.gov/show/NCT02993068)
Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
NCT ID: NCT05573126 (https://classic.clinicaltrials.gov/show/NCT05573126)
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT ID: NCT03095352 (https://classic.clinicaltrials.gov/show/NCT03095352)
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT ID: NCT05896189 (https://classic.clinicaltrials.gov/show/NCT05896189)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://classic.clinicaltrials.gov/show/NCT05483491)
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
NCT ID: NCT03930680 (https://classic.clinicaltrials.gov/show/NCT03930680)
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT ID: NCT05747794 (https://classic.clinicaltrials.gov/show/NCT05747794)
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT ID: NCT05514054 (https://classic.clinicaltrials.gov/show/NCT05514054)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382286 (https://classic.clinicaltrials.gov/show/NCT05382286)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382299 (https://classic.clinicaltrials.gov/show/NCT05382299)
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://classic.clinicaltrials.gov/show/NCT01766297)
Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial
NCT ID: NCT06016725 (https://classic.clinicaltrials.gov/show/NCT06016725)
Study of Aerobic Training for People Receiving Chemotherapy for Breast Cancer
NCT ID: NCT05716893 (https://classic.clinicaltrials.gov/show/NCT05716893)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://classic.clinicaltrials.gov/show/NCT04683679)
Mammography and Breast Arterial Calcification: An Information-Sharing Trial
NCT ID: NCT04983875 (https://classic.clinicaltrials.gov/show/NCT04983875)
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
NCT ID: NCT04669301 (https://classic.clinicaltrials.gov/show/NCT04669301)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://classic.clinicaltrials.gov/show/NCT05607004)
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://classic.clinicaltrials.gov/show/NCT05146297)
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03742102 (https://classic.clinicaltrials.gov/show/NCT03742102)
TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol
NCT ID: NCT03879629 (https://classic.clinicaltrials.gov/show/NCT03879629)
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT ID: NCT05653752 (https://classic.clinicaltrials.gov/show/NCT05653752)
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT ID: NCT05721248 (https://classic.clinicaltrials.gov/show/NCT05721248)
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT ID: NCT05545150 (https://classic.clinicaltrials.gov/show/NCT05545150)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://classic.clinicaltrials.gov/show/NCT05467891)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
NCT ID: NCT06315296 (https://classic.clinicaltrials.gov/show/NCT06315296)
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
NCT ID: NCT05554354 (https://classic.clinicaltrials.gov/show/NCT05554354)
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT ID: NCT05323955 (https://classic.clinicaltrials.gov/show/NCT05323955)
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT ID: NCT02276443 (https://classic.clinicaltrials.gov/show/NCT02276443)
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://classic.clinicaltrials.gov/show/NCT05568472)
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT ID: NCT04090398 (https://classic.clinicaltrials.gov/show/NCT04090398)
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://classic.clinicaltrials.gov/show/NCT03606967)
The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema
NCT ID: NCT05890677 (https://classic.clinicaltrials.gov/show/NCT05890677)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://classic.clinicaltrials.gov/show/NCT04468061)
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT ID: NCT05900986 (https://classic.clinicaltrials.gov/show/NCT05900986)
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT ID: NCT01570998 (https://classic.clinicaltrials.gov/show/NCT01570998)
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
NCT ID: NCT05076591 (https://classic.clinicaltrials.gov/show/NCT05076591)
Mobile Health for Adherence in Breast Cancer Patients
NCT ID: NCT06112613 (https://classic.clinicaltrials.gov/show/NCT06112613)
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT06016738 (https://classic.clinicaltrials.gov/show/NCT06016738)
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://classic.clinicaltrials.gov/show/NCT04389281)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://classic.clinicaltrials.gov/show/NCT05673200)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://classic.clinicaltrials.gov/show/NCT06058377)
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://classic.clinicaltrials.gov/show/NCT04584255)
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT ID: NCT03562637 (https://classic.clinicaltrials.gov/show/NCT03562637)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://classic.clinicaltrials.gov/show/NCT05929768)
A Study of Mental Health Care in People With Cancer
NCT ID: NCT06037954 (https://classic.clinicaltrials.gov/show/NCT06037954)
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
NCT ID: NCT05587972 (https://classic.clinicaltrials.gov/show/NCT05587972)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://classic.clinicaltrials.gov/show/NCT04150042)
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT ID: NCT04975308 (https://classic.clinicaltrials.gov/show/NCT04975308)
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT ID: NCT02912312 (https://classic.clinicaltrials.gov/show/NCT02912312)
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT ID: NCT05262400 (https://classic.clinicaltrials.gov/show/NCT05262400)
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT ID: NCT04569747 (https://classic.clinicaltrials.gov/show/NCT04569747)
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT ID: NCT03463954 (https://classic.clinicaltrials.gov/show/NCT03463954)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://classic.clinicaltrials.gov/show/NCT05372640)
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT ID: NCT06144164 (https://classic.clinicaltrials.gov/show/NCT06144164)
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT ID: NCT06246968 (https://classic.clinicaltrials.gov/show/NCT06246968)
MARGetuximab Or Trastuzumab (MARGOT)
NCT ID: NCT04425018 (https://classic.clinicaltrials.gov/show/NCT04425018)
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT ID: NCT03598257 (https://classic.clinicaltrials.gov/show/NCT03598257)
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT ID: NCT04549571 (https://classic.clinicaltrials.gov/show/NCT04549571)
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
NCT ID: NCT05694364 (https://classic.clinicaltrials.gov/show/NCT05694364)
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://classic.clinicaltrials.gov/show/NCT04553770)
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
NCT ID: NCT02620852 (https://classic.clinicaltrials.gov/show/NCT02620852)
A Study of Blood Pressure Control During Cancer Treatment
NCT ID: NCT06023576 (https://classic.clinicaltrials.gov/show/NCT06023576)
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT ID: NCT03723928 (https://classic.clinicaltrials.gov/show/NCT03723928)
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT ID: NCT04197687 (https://classic.clinicaltrials.gov/show/NCT04197687)
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT ID: NCT02488967 (https://classic.clinicaltrials.gov/show/NCT02488967)
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
NCT ID: NCT04711109 (https://classic.clinicaltrials.gov/show/NCT04711109)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://classic.clinicaltrials.gov/show/NCT04899908)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://classic.clinicaltrials.gov/show/NCT06120283)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT ID: NCT05216432 (https://classic.clinicaltrials.gov/show/NCT05216432)
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
NCT ID: NCT04871516 (https://classic.clinicaltrials.gov/show/NCT04871516)
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT ID: NCT04647916 (https://classic.clinicaltrials.gov/show/NCT04647916)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://classic.clinicaltrials.gov/show/NCT03971409)
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT ID: NCT03418961 (https://classic.clinicaltrials.gov/show/NCT03418961)
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://classic.clinicaltrials.gov/show/NCT04457596)
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT ID: NCT02945579 (https://classic.clinicaltrials.gov/show/NCT02945579)
Roll-over Study to Allow Continued Access to Ribociclib
NCT ID: NCT05161195 (https://classic.clinicaltrials.gov/show/NCT05161195)
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT ID: NCT05645380 (https://classic.clinicaltrials.gov/show/NCT05645380)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://classic.clinicaltrials.gov/show/NCT05812807)
Phase 1b Combo w/ Ribociclib and Alpelisib
NCT ID: NCT05508906 (https://classic.clinicaltrials.gov/show/NCT05508906)
A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NCT ID: NCT05910294 (https://classic.clinicaltrials.gov/show/NCT05910294)
Social Risk Factors and Discrimination in Cancer Survivorship
NCT ID: NCT05301114 (https://classic.clinicaltrials.gov/show/NCT05301114)
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT ID: NCT05720039 (https://classic.clinicaltrials.gov/show/NCT05720039)
RAPA-201 Therapy of Solid Tumors
NCT ID: NCT05144698 (https://classic.clinicaltrials.gov/show/NCT05144698)
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies
NCT ID: NCT06052852 (https://classic.clinicaltrials.gov/show/NCT06052852)
PRO1107 in Patients With Advanced Solid Tumors
NCT ID: NCT06171789 (https://classic.clinicaltrials.gov/show/NCT06171789)
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT ID: NCT04616248 (https://classic.clinicaltrials.gov/show/NCT04616248)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT ID: NCT05076760 (https://classic.clinicaltrials.gov/show/NCT05076760)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://classic.clinicaltrials.gov/show/NCT05534438)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT ID: NCT03524430 (https://classic.clinicaltrials.gov/show/NCT03524430)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
NCT ID: NCT05386108 (https://classic.clinicaltrials.gov/show/NCT05386108)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://classic.clinicaltrials.gov/show/NCT04282044)
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
NCT ID: NCT03401385 (https://classic.clinicaltrials.gov/show/NCT03401385)
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT ID: NCT04266249 (https://classic.clinicaltrials.gov/show/NCT04266249)
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT ID: NCT06103669 (https://classic.clinicaltrials.gov/show/NCT06103669)
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
NCT ID: NCT05967533 (https://classic.clinicaltrials.gov/show/NCT05967533)
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://classic.clinicaltrials.gov/show/NCT04084730)
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
NCT ID: NCT04982926 (https://classic.clinicaltrials.gov/show/NCT04982926)
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT ID: NCT05514717 (https://classic.clinicaltrials.gov/show/NCT05514717)
F-Tryptophan PET/CT in Human Cancers
NCT ID: NCT05556473 (https://classic.clinicaltrials.gov/show/NCT05556473)
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT ID: NCT06299163 (https://classic.clinicaltrials.gov/show/NCT06299163)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
NCT ID: NCT05232916 (https://classic.clinicaltrials.gov/show/NCT05232916)
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery.
NCT ID: NCT05113927 (https://classic.clinicaltrials.gov/show/NCT05113927)
The Effect of Acupuncture on Cancer-Related Cognitive Difficulties
NCT ID: NCT04837820 (https://classic.clinicaltrials.gov/show/NCT04837820)
Home-Based Physical Activity Intervention for Taxane-Induced CIPN
NCT ID: NCT04621721 (https://classic.clinicaltrials.gov/show/NCT04621721)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://classic.clinicaltrials.gov/show/NCT03351348)
DISCO: A Patient Intervention to Reduce the Financial Burden of Cancer
NCT ID: NCT04766190 (https://classic.clinicaltrials.gov/show/NCT04766190)
Testing a New Imaging Agent to Identify Cancer
NCT ID: NCT04692831 (https://classic.clinicaltrials.gov/show/NCT04692831)
Adaptive Symptom Self-Management Immunotherapy Study
NCT ID: NCT05715255 (https://classic.clinicaltrials.gov/show/NCT05715255)
Improving Care After Inherited Cancer Testing
NCT ID: NCT04763915 (https://classic.clinicaltrials.gov/show/NCT04763915)
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
NCT ID: NCT04541381 (https://classic.clinicaltrials.gov/show/NCT04541381)
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
NCT ID: NCT03937154 (https://classic.clinicaltrials.gov/show/NCT03937154)
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT ID: NCT04751435 (https://classic.clinicaltrials.gov/show/NCT04751435)
A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
NCT ID: NCT05215769 (https://classic.clinicaltrials.gov/show/NCT05215769)
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://classic.clinicaltrials.gov/show/NCT01042379)
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://classic.clinicaltrials.gov/show/NCT05892068)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT ID: NCT05751668 (https://classic.clinicaltrials.gov/show/NCT05751668)
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05490472 (https://classic.clinicaltrials.gov/show/NCT05490472)
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT ID: NCT03011684 (https://classic.clinicaltrials.gov/show/NCT03011684)
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT ID: NCT04964934 (https://classic.clinicaltrials.gov/show/NCT04964934)
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
NCT ID: NCT05677048 (https://classic.clinicaltrials.gov/show/NCT05677048)
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://classic.clinicaltrials.gov/show/NCT05868226)
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://classic.clinicaltrials.gov/show/NCT06157892)
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT05765851 (https://classic.clinicaltrials.gov/show/NCT05765851)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://classic.clinicaltrials.gov/show/NCT05768139)
Video Education With Result Dependent dIsclosure
NCT ID: NCT05225428 (https://classic.clinicaltrials.gov/show/NCT05225428)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://classic.clinicaltrials.gov/show/NCT05000294)
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT ID: NCT05969860 (https://classic.clinicaltrials.gov/show/NCT05969860)
Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://classic.clinicaltrials.gov/show/NCT04475640)
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT ID: NCT05453825 (https://classic.clinicaltrials.gov/show/NCT05453825)
Adapting the Tumor Board Model for Mental Illness and Cancer
NCT ID: NCT05837598 (https://classic.clinicaltrials.gov/show/NCT05837598)
With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://classic.clinicaltrials.gov/show/NCT05721976)
The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment
NCT ID: NCT05458284 (https://classic.clinicaltrials.gov/show/NCT05458284)
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT ID: NCT04042701 (https://classic.clinicaltrials.gov/show/NCT04042701)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://classic.clinicaltrials.gov/show/NCT03604315)
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
NCT ID: NCT02993159 (https://classic.clinicaltrials.gov/show/NCT02993159)
Culturally Aware AET Non-Initiation Intervention
NCT ID: NCT05465408 (https://classic.clinicaltrials.gov/show/NCT05465408)
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
NCT ID: NCT05559164 (https://classic.clinicaltrials.gov/show/NCT05559164)
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT ID: NCT06334432 (https://classic.clinicaltrials.gov/show/NCT06334432)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://classic.clinicaltrials.gov/show/NCT03808337)
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT ID: NCT04147494 (https://classic.clinicaltrials.gov/show/NCT04147494)
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT05593094 (https://classic.clinicaltrials.gov/show/NCT05593094)
Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://classic.clinicaltrials.gov/show/NCT04967976)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT ID: NCT04650256 (https://classic.clinicaltrials.gov/show/NCT04650256)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://classic.clinicaltrials.gov/show/NCT06188520)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://classic.clinicaltrials.gov/show/NCT04222413)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://classic.clinicaltrials.gov/show/NCT06257264)
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT ID: NCT03504488 (https://classic.clinicaltrials.gov/show/NCT03504488)
Integrated Actionable Aging Assessment for Cancer Patients Pilot
NCT ID: NCT05871008 (https://classic.clinicaltrials.gov/show/NCT05871008)
Methods for Increasing Genetic Testing Uptake in Michigan
NCT ID: NCT05162846 (https://classic.clinicaltrials.gov/show/NCT05162846)
The PROMISE Study: Duavee in Women With DCIS
NCT ID: NCT02694809 (https://classic.clinicaltrials.gov/show/NCT02694809)
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ
NCT ID: NCT04570956 (https://classic.clinicaltrials.gov/show/NCT04570956)
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT ID: NCT04496739 (https://classic.clinicaltrials.gov/show/NCT04496739)
Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)
NCT ID: NCT05056077 (https://classic.clinicaltrials.gov/show/NCT05056077)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://classic.clinicaltrials.gov/show/NCT06253520)
PF-07104091 as a Single Agent and in Combination Therapy
NCT ID: NCT04553133 (https://classic.clinicaltrials.gov/show/NCT04553133)
Choices About Genetic Testing And Learning Your Risk With Smart Technology
NCT ID: NCT06184867 (https://classic.clinicaltrials.gov/show/NCT06184867)
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT ID: NCT05226871 (https://classic.clinicaltrials.gov/show/NCT05226871)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://classic.clinicaltrials.gov/show/NCT03412877)
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
NCT ID: NCT05848739 (https://classic.clinicaltrials.gov/show/NCT05848739)
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT ID: NCT03740256 (https://classic.clinicaltrials.gov/show/NCT03740256)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://classic.clinicaltrials.gov/show/NCT05313191)
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT ID: NCT03960463 (https://classic.clinicaltrials.gov/show/NCT03960463)
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers
NCT ID: NCT04072393 (https://classic.clinicaltrials.gov/show/NCT04072393)
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
NCT ID: NCT04038619 (https://classic.clinicaltrials.gov/show/NCT04038619)
Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://classic.clinicaltrials.gov/show/NCT06165419)
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
NCT ID: NCT05989724 (https://classic.clinicaltrials.gov/show/NCT05989724)
CALM: Managing Distress in Malignant Brain Cancer
NCT ID: NCT06180460 (https://classic.clinicaltrials.gov/show/NCT06180460)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT ID: NCT04119024 (https://classic.clinicaltrials.gov/show/NCT04119024)
Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://classic.clinicaltrials.gov/show/NCT04589468)
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT ID: NCT05735080 (https://classic.clinicaltrials.gov/show/NCT05735080)
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06264921 (https://classic.clinicaltrials.gov/show/NCT06264921)
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT ID: NCT05082610 (https://classic.clinicaltrials.gov/show/NCT05082610)
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT ID: NCT05180474 (https://classic.clinicaltrials.gov/show/NCT05180474)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT ID: NCT03233191 (https://classic.clinicaltrials.gov/show/NCT03233191)
Women's Interventions for Sexual Health: WISH
NCT ID: NCT05692960 (https://classic.clinicaltrials.gov/show/NCT05692960)
Wrist Cooling for Hot Flashes Clinical Trial
NCT ID: NCT05595213 (https://classic.clinicaltrials.gov/show/NCT05595213)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://classic.clinicaltrials.gov/show/NCT04606446)
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
NCT ID: NCT04593277 (https://classic.clinicaltrials.gov/show/NCT04593277)
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT ID: NCT05274451 (https://classic.clinicaltrials.gov/show/NCT05274451)
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
NCT ID: NCT05830097 (https://classic.clinicaltrials.gov/show/NCT05830097)
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT ID: NCT05283330 (https://classic.clinicaltrials.gov/show/NCT05283330)
(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://classic.clinicaltrials.gov/show/NCT05252416)
TH1902 in Patients With Advanced Solid Tumors
NCT ID: NCT04706962 (https://classic.clinicaltrials.gov/show/NCT04706962)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://classic.clinicaltrials.gov/show/NCT06022029)
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT ID: NCT04180371 (https://classic.clinicaltrials.gov/show/NCT04180371)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)
PRO1184 for Advanced Solid Tumors
NCT ID: NCT05579366 (https://classic.clinicaltrials.gov/show/NCT05579366)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://classic.clinicaltrials.gov/show/NCT05123482)
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT ID: NCT05650879 (https://classic.clinicaltrials.gov/show/NCT05650879)
A Study of XMT-1660 in Participants With Solid Tumors
NCT ID: NCT05377996 (https://classic.clinicaltrials.gov/show/NCT05377996)
Interventions to Decrease Financial Toxicity
NCT ID: NCT05939440 (https://classic.clinicaltrials.gov/show/NCT05939440)
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT ID: NCT06084481 (https://classic.clinicaltrials.gov/show/NCT06084481)
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://classic.clinicaltrials.gov/show/NCT04787042)
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT ID: NCT04557449 (https://classic.clinicaltrials.gov/show/NCT04557449)
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT ID: NCT05565417 (https://classic.clinicaltrials.gov/show/NCT05565417)
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT ID: NCT05511844 (https://classic.clinicaltrials.gov/show/NCT05511844)
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)
Study to Evaluate CCS1477 in Advanced Tumours
NCT ID: NCT03568656 (https://classic.clinicaltrials.gov/show/NCT03568656)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://classic.clinicaltrials.gov/show/NCT05864144)
A Study of SGN-B7H4V in Advanced Solid Tumors
NCT ID: NCT05194072 (https://classic.clinicaltrials.gov/show/NCT05194072)
Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://classic.clinicaltrials.gov/show/NCT05349227)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://classic.clinicaltrials.gov/show/NCT04494945)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://classic.clinicaltrials.gov/show/NCT04144023)
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT ID: NCT06065059 (https://classic.clinicaltrials.gov/show/NCT06065059)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT ID: NCT05891171 (https://classic.clinicaltrials.gov/show/NCT05891171)
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT ID: NCT05585034 (https://classic.clinicaltrials.gov/show/NCT05585034)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://classic.clinicaltrials.gov/show/NCT05837767)
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT ID: NCT04478279 (https://classic.clinicaltrials.gov/show/NCT04478279)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
NCT ID: NCT04278144 (https://classic.clinicaltrials.gov/show/NCT04278144)
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT ID: NCT06238479 (https://classic.clinicaltrials.gov/show/NCT06238479)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT ID: NCT04561362 (https://classic.clinicaltrials.gov/show/NCT04561362)
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
NCT ID: NCT06218303 (https://classic.clinicaltrials.gov/show/NCT06218303)
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://classic.clinicaltrials.gov/show/NCT05218044)
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT ID: NCT05902988 (https://classic.clinicaltrials.gov/show/NCT05902988)
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT ID: NCT04588246 (https://classic.clinicaltrials.gov/show/NCT04588246)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT ID: NCT05787587 (https://classic.clinicaltrials.gov/show/NCT05787587)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://classic.clinicaltrials.gov/show/NCT05107674)
A Study of SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://classic.clinicaltrials.gov/show/NCT05208762)
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
NCT ID: NCT05544929 (https://classic.clinicaltrials.gov/show/NCT05544929)
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NCT ID: NCT05108298 (https://classic.clinicaltrials.gov/show/NCT05108298)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://classic.clinicaltrials.gov/show/NCT04644068)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://classic.clinicaltrials.gov/show/NCT04895709)
Assessing the Immunogenicity of pING-hHER3FL
NCT ID: NCT03832855 (https://classic.clinicaltrials.gov/show/NCT03832855)
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
NCT ID: NCT02872025 (https://classic.clinicaltrials.gov/show/NCT02872025)
RANKL Inhibition and Mammographic Breast Density
NCT ID: NCT04067726 (https://classic.clinicaltrials.gov/show/NCT04067726)
Onco-primary Care Networking to Support TEAM-based Care
NCT ID: NCT04258813 (https://classic.clinicaltrials.gov/show/NCT04258813)
A Study of SGN-B6A in Advanced Solid Tumors
NCT ID: NCT04389632 (https://classic.clinicaltrials.gov/show/NCT04389632)
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT ID: NCT03556228 (https://classic.clinicaltrials.gov/show/NCT03556228)
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT04450732 (https://classic.clinicaltrials.gov/show/NCT04450732)
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT05576077 (https://classic.clinicaltrials.gov/show/NCT05576077)
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
NCT ID: NCT05007106 (https://classic.clinicaltrials.gov/show/NCT05007106)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://classic.clinicaltrials.gov/show/NCT05877599)
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT ID: NCT05932862 (https://classic.clinicaltrials.gov/show/NCT05932862)
Study of Oral MRT-2359 in Selected Cancer Patients
NCT ID: NCT05546268 (https://classic.clinicaltrials.gov/show/NCT05546268)
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
NCT ID: NCT05827614 (https://classic.clinicaltrials.gov/show/NCT05827614)
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT ID: NCT05708950 (https://classic.clinicaltrials.gov/show/NCT05708950)
Ruxolitinib for Premalignant Breast Disease
NCT ID: NCT02928978 (https://classic.clinicaltrials.gov/show/NCT02928978)
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://classic.clinicaltrials.gov/show/NCT05703269)
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
NCT ID: NCT03075072 (https://classic.clinicaltrials.gov/show/NCT03075072)
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT ID: NCT03589339 (https://classic.clinicaltrials.gov/show/NCT03589339)
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT ID: NCT05035407 (https://classic.clinicaltrials.gov/show/NCT05035407)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05070247 (https://classic.clinicaltrials.gov/show/NCT05070247)
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT ID: NCT03129139 (https://classic.clinicaltrials.gov/show/NCT03129139)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
NCT ID: NCT05259696 (https://classic.clinicaltrials.gov/show/NCT05259696)
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://classic.clinicaltrials.gov/show/NCT04913337)
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
NCT ID: NCT05500508 (https://classic.clinicaltrials.gov/show/NCT05500508)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies
NCT ID: NCT04152499 (https://classic.clinicaltrials.gov/show/NCT04152499)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
NCT ID: NCT05683418 (https://classic.clinicaltrials.gov/show/NCT05683418)
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT ID: NCT04969835 (https://classic.clinicaltrials.gov/show/NCT04969835)
The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT ID: NCT04768868 (https://classic.clinicaltrials.gov/show/NCT04768868)
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT ID: NCT05898399 (https://classic.clinicaltrials.gov/show/NCT05898399)
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
NCT ID: NCT04712721 (https://classic.clinicaltrials.gov/show/NCT04712721)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://classic.clinicaltrials.gov/show/NCT06270706)
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
NCT ID: NCT05712889 (https://classic.clinicaltrials.gov/show/NCT05712889)
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT ID: NCT03899792 (https://classic.clinicaltrials.gov/show/NCT03899792)
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT ID: NCT03157128 (https://classic.clinicaltrials.gov/show/NCT03157128)
A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://classic.clinicaltrials.gov/show/NCT05150691)
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT ID: NCT02264678 (https://classic.clinicaltrials.gov/show/NCT02264678)
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT ID: NCT02000089 (https://classic.clinicaltrials.gov/show/NCT02000089)
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
NCT ID: NCT04890613 (https://classic.clinicaltrials.gov/show/NCT04890613)
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
NCT ID: NCT05941507 (https://classic.clinicaltrials.gov/show/NCT05941507)
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT ID: NCT04225117 (https://classic.clinicaltrials.gov/show/NCT04225117)
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
NCT ID: NCT04931823 (https://classic.clinicaltrials.gov/show/NCT04931823)
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT ID: NCT05888831 (https://classic.clinicaltrials.gov/show/NCT05888831)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05785741 (https://classic.clinicaltrials.gov/show/NCT05785741)
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT ID: NCT04373564 (https://classic.clinicaltrials.gov/show/NCT04373564)
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT ID: NCT05238922 (https://classic.clinicaltrials.gov/show/NCT05238922)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://classic.clinicaltrials.gov/show/NCT04300556)
Study of DF1001 in Patients With Advanced Solid Tumors
NCT ID: NCT04143711 (https://classic.clinicaltrials.gov/show/NCT04143711)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://classic.clinicaltrials.gov/show/NCT05325866)
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT ID: NCT05537740 (https://classic.clinicaltrials.gov/show/NCT05537740)
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT03821935 (https://classic.clinicaltrials.gov/show/NCT03821935)
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2
NCT ID: NCT05958199 (https://classic.clinicaltrials.gov/show/NCT05958199)
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
NCT ID: NCT05297734 (https://classic.clinicaltrials.gov/show/NCT05297734)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.